Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Johnson & Johnson’s RYBREVANT FASPRO™ Receives FDA Breakthrough Therapy Designation for Advanced Head and Neck Cancer
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for adults...
HERNEXEOS Receives FDA Approval for Advanced HER2-Mutant NSCLC
The U.S. Food and Drug Administration has approved HERNEXEOS (zongertinib tablets), developed by Boehringer Ingelheim, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) whose tumours...
Alkermes Secures FDA Breakthrough Therapy Status for Alixorexton in Narcolepsy Type 1
Alkermes plc has announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1)....
Relay Therapeutics’ Zovegalisib Granted FDA Breakthrough Therapy Status for PIK3CA-Mutant Breast Cancer
Relay Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to zovegalisib (RLY-2608) in combination...
Encoded Therapeutics ETX101 Receives FDA Breakthrough Therapy Designation for Dravet Syndrome
Encoded Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ETX101 for the treatment of SCN1A-positive Dravet syndrome....
Novartis’ Ianalumab Secures FDA Breakthrough Therapy Status for Sjögren’s disease
Novartis has reported that the US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to ianalumab for the treatment of Sjögren’s disease...
Altimmune Secures FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune, Inc., has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment...
BMS’s Breyanzi Receives FDA Approval in Relapsed/Refractory Marginal Zone Lymphoma
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed CAR T cell therapy, for adult patients with relapsed or refractory...
FDA Grants Breakthrough Therapy Designation to Adrabetadex for Infantile Onset Niemann Pick Type C
Beren Therapeutics P.B.C., parent company of Mandos LLC, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC)....
PBS Biotech Launches Breakthrough MiniPRO™ Multi-Parallel Bioreactor Platform for Cell Therapy Process Development
PBS Biotech has unveiled MiniPRO™, a new multi-parallel Vertical-Wheel® bioreactor platform designed to accelerate high-throughput cell therapy process development....
